Replies to post #248616 on Anavex Life Sciences Corp (AVXL)

[F1ash]

It is a difficult world we live in when a discussion
of Anavex proves impossible due to a basic misunderstanding of
serum concentration and dosage,

That confusion is intentional imho. How could management have explained why they did not include the “effective” doses from the 2a in the 2b/3 trial. That “T” thing would have cropped it’s ugly head.


Does this quote from Anavex’s presentation clear things up?




“97% Consistency: MMSE, ADCS-ADL and EEG/ERPs: Identified relations show that high dose (concentration) is linked to improved response and low dose (concentration) to poor response

The doses they were comparing were 10,20,30,40 and 50 mgs.



Just because they are now calling 10 low and 20 high doesn’t explain a darn thing imho.




Page 22



https://www.anavex.com/wp-content/uploads/2018/05/Anavex-ANAVEX2-73-CTAD-Phase-2a-November-2017.pdf